Choate Investment Advisors Has $865,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Choate Investment Advisors grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,091 shares of the company’s stock after acquiring an additional 39 shares during the period. Choate Investment Advisors’ holdings in IDEXX Laboratories were worth $865,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in IDXX. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth about $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $38,000. Finally, Crews Bank & Trust acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $415.30 on Monday. The company has a market capitalization of $33.78 billion, a P/E ratio of 38.92, a PEG ratio of 3.41 and a beta of 1.39. The company has a fifty day moving average price of $438.03 and a 200-day moving average price of $446.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Leerink Partners began coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.